"Through our exclusive licensing agreement with the Institute of Cell Therapy (ICT) in Kiev, Ukraine, Stem Cell Therapy International is pleased to welcome to our working Scientific Advisory Board four of the Institute's senior doctors and researchers, who have been responsible for 26 patents in stem cell production and cryo-freezing processes," said Calvin Cao, SCTI chairman and chief executive officer.

Joining the advisory board are: Yuriv V. Gladkikh, MD, PhD; Galina S. Lobyntseva, BD, PhD; Dmitriy V. Lobyntsev and Vladimir Yu. Gladkikh.

Dr. Yuriv Gladkikh, a graduate of the Kiev Medical Institute of A.A. Bohomolets, has worked in Europe and Asia in the field of management and organization of health protection, as well as research in cryobiology and cryo-medicine, internal diseases, virology, quantum, cell and tissue therapy, modern methods of diagnostics and laboratory researches, epidemiology and infectious diseases.

Dr. Galina Lobyntseva, a director of ICT and a graduate of Kharkov State University with a specialty in genetics, has been in the forefront of research in embryonic hemopoitic cells and work on methods for long-term storage of the cells at low temperatures. She has been working with Cryobiology and Cryomedicine at the National Academy of Sciences of the Ukraine since it's foundation in 1972. Dr. Lobyntseva has received 15 authors' certificates and patents.

Dimitriy Lobyntsev, a graduate of the Odessa Academy of Cold with a specialty in cryogenic technique and technologies, is the author of five patents in the Ukraine and co-author of volume one of "Human Stem Embryonic Hemopoitic Cells. Theory and Clinical Practice."

Vladimir Gladkikh, a graduate of the Vinnitsa National Medical University with a specialty in surgery, is engaged in research in the field of vascular surgery.

"The unique role SCTI's working Scientific Advisory Board encompasses both classical identification and evaluation of research in the field of stem cell transplantation therapy as well as the hands-on evaluation and care of patients for their suitability for transplantation treatment," Cao said. "This powerful combination is designed to help speed the broader use of stem cell transplantation."

Stem cell transplantation therapy is a field of medicine, which uses techniques and technologies that rely on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. This therapy is similar to the process of organ transplantation, only the treatment consists of the transplantation of stem cells into the body rather than entire organs, thus eliminating any chance of rejection or the need for immunosuppression drugs. These new techniques are being applied to finding a cure for a wide range of human disorders, including neurological diseases such as Alzheimer's, Parkinson's Disease, ALS (Lou Gehrig's disease), leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer and the side effects of chemotherapy.

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion was created to fund stem cell research. Since then three other states New Jersey, Connecticut and Illinois, have allocated funds for stem cell research. Among the leading public companies in the U.S. in the field of stem cell technology are A.C.T. Holdings, Inc.; ViaCell; Geron; StemCells, Inc., and Aastrom Biosciences Inc. For additional information, please visit our website @ www.scticorp.com.

About Stem Cell Therapy International

Stem Cell Therapy International Corp. (SCTI) is in the field of regenerative medicine. SCTI provides new stem cell solutions, which are being used in the treatment of patients suffering from degenerative disorders of the human body. SCTI operates in conjunction with advanced medical facilities devoted to the treatment of human physical disorders with stem cell transplantation therapy. The company intends to continue to establish relationships with highly specialized, professional medical treatment centers outside of the United States that will treat patients with the stem cell transplantation therapy. In addition, SCTI intends to provide biological solutions containing new stem cell products in the United States to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials.

Forward Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.

Source Stem Cell Therapy International